Press Releases See All 03/16/2023 Sarepta Therapeutics Announces Advisory Committee Meeting will be Held for SRP-9001 02/28/2023 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 02/28/2023 Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments Stories & Perspectives Filter by: Filter by: All Advocates & Innovators Culture & Community Inside the Science Patient Voices Filter by: AllAdvocates & InnovatorsCulture & CommunityInside the SciencePatient Voices Advocates & Innovators A passion for patients, an influential mentor and a change in plans: Meet Danielle Griffin Patient Voices Creating pathways to LGMD genetic diagnosis: Spotlight on LGMD Grant Award recipient Advocates & Innovators Ensuring the Safety of Clinical Trial Participants: Meet Eddie Darton, M.D. Advocates & Innovators Dragging tomorrow into today: Meet Rachael Potter, Ph.D. Inside the Science Understanding external controls and their importance to clinical trials for rare diseases Inside the Science Meaningful measure: Understanding the NSAA, an important Duchenne functional-assessment tool Culture & Community What’d you do this summer? Our summer interns share lessons learned Culture & Community Pride Proud: What belonging feels like and why representation matters Advocates & Innovators A Conversation with CFO Ian Estepan, recipient of the 2022 CFO of the Year award from the Boston Business Journal Inside the Science Seroprevalence: What patients should know about pre-existing antibodies to gene therapy Inside the Science Patient registries: A catalyst for developing new therapies for rare diseases Inside the Science Measurements Used in Clinical Trials for Duchenne Muscular Dystrophy – an Overview Advocates & Innovators How a collaboration in the lab led to a seat at the table in Sarepta’s Gene Editing Innovation Center Culture & Community Giving Thanks for Our Employees’ Incredible Dedication: Six Employees Explain Why Sarepta is a Top Place to Work Inside the Science Welcome to GT‐FAQ! Advocates & Innovators Expanding Access to Newborn Screening for Those with Rare Diseases Patient Voices Patiently Waiting Advocates & Innovators From Art to Science: How One Sarepta Scientist Brings the Arts into the Lab Patient Voices Advocacy Community Unites to Support Families Culture & Community How Sarepta Infused its Corporate Brand with Urgency and Optimism on Behalf of Patients Inside the Science What’s in a name? A lot, for the limb-girdle muscular dystrophy community. Media Library Sarepta Corporate Logos, Images & Fact Sheets View All Press Contact Tracy Sorrentino Executive Director, Public Relations Sarepta Therapeutics, Inc.[email protected]617-274-4052
02/28/2023 Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments
Advocates & Innovators A passion for patients, an influential mentor and a change in plans: Meet Danielle Griffin
Inside the Science Understanding external controls and their importance to clinical trials for rare diseases
Inside the Science Meaningful measure: Understanding the NSAA, an important Duchenne functional-assessment tool
Advocates & Innovators A Conversation with CFO Ian Estepan, recipient of the 2022 CFO of the Year award from the Boston Business Journal
Inside the Science Seroprevalence: What patients should know about pre-existing antibodies to gene therapy
Inside the Science Measurements Used in Clinical Trials for Duchenne Muscular Dystrophy – an Overview
Advocates & Innovators How a collaboration in the lab led to a seat at the table in Sarepta’s Gene Editing Innovation Center
Culture & Community Giving Thanks for Our Employees’ Incredible Dedication: Six Employees Explain Why Sarepta is a Top Place to Work
Culture & Community How Sarepta Infused its Corporate Brand with Urgency and Optimism on Behalf of Patients